AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
New Drug Continues to Show Promise in Early Testing.
2000 DEC 28 - (NewsRx.com & NewsRx.net) -- An experimental targeted therapy for chronic myelogenous leukemia (CML) continues to show promise in early testing, and it may help to battle the disease even at its most aggressive and deadly stage, according to a researcher at the University of California at Los Angeles' (UCLA) Jonsson Cancer Center.
Dr. Charles Sawyers studied the drug Glivec, formerly known as STI-571, in CML patients in myeloid blast crisis, the final stage of the disease that is usually fatal within four to six months. Sawyers is among several researchers who presented results from the second phase of clinical testing of the drug December 4, 2000, at the annual meeting of the American Society of Hematology (ASH) in San Francisco, California.
Glivec, taken once a day…
- More Than Fifty Abstracts on Novartis Investigational Leukemia Agent...
- Press release article from: PR Newswire December 2, 2000 700+ words
...the effectiveness of Glivec in patients with each...Leukemia Kantarjian H, Sawyers C, Hochhaus A, Guilhot...the latest findings on Glivec: 1. A New Beginning...be chaired by Charles Sawyers, MD, Professor of Medicine...lead investigator on Glivec, will present results...
- MORE THAN FIFTY ABSTRACTS ON NOVARTIS INVESTIGATIONAL LEUKEMIA AGENT GLIVEC,...
- Press release article from: PR Newswire December 4, 2000 700+ words
...the effectiveness of Glivec in patients with each...Leukemia Kantarjian H, Sawyers C, Hochhaus A, Guilhot...the latest findings on Glivec: 1. A New Beginning...be chaired by Charles Sawyers, MD, Professor of Medicine...lead investigator on Glivec, will present results...
- Trials affirm value of drug.(STI-571, or Glivec)(Brief Article)
- Magazine article from: Science News N.S. December 16, 2000 700+ words
...99, p. 372). Now, further testing of STI-571, called Glivec by Novartis Oncology of East Hanover, N.J., supports the...During the 6 months after treatment began, hematologist Charles Sawyers of UCLA reports, 161 of the patients improved. However...
- Glivec substantially reduces risk of cancer returning in patients with...
- News wire article from: Europe Intelligence Wire March 18, 2009 700+ words
...stromal tumor (GIST) patients taking Glivec vs. 83% for patients taking placebo...median of two years after surgery[3] Glivec is the only treatment in the US and Switzerland...upcoming print issue of The Lancet show that Glivec (imatinib), when taken after surgery...
- Glivec recommended for use in Europe as first post-surgery treatment for...
- News wire article from: Europe Intelligence Wire March 19, 2009 700+ words
...Use of Glivec after surgery (adjuvant setting) shows...for Europe follows recent approvals of Glivec in the adjuvant setting in the US and...supporting European Union (EU) approval of Glivec (imatinib) as a post-surgery treatment...
- Glivec approved in EU as first post-surgery therapy to reduce risk of cancer...
- News wire article from: Europe Intelligence Wire May 7, 2009 700+ words
...Post-surgery use of Glivec shown to reduce the risk of gastrointestinal...cancer[2],[3] Basel, May 7, 2009 - Glivec (imatinib) received approval from the...treated with post-surgery, or adjuvant, Glivec, the risk of recurrence was reduced by...
- Glivec receives additional EU approvals for use in treating a rapidly...
- News wire article from: Europe Intelligence Wire September 19, 2006 700+ words
...Glivec in combination with standard chemotherapy...DFSP) represents the second approval for Glivec as treatment for a solid tumor * Approvals...additional European Union approvals for Glivec (imatinib)* to help patients with a...
- Glivec demonstrates highest five-year overall survival rate in history of...
- News wire article from: Europe Intelligence Wire December 6, 2006 700+ words
...CML or prior bone marrow transplantation Glivec results improve with long-term use...year of study Long-term data confirm Glivec as a generally well-tolerated therapy...England Journal of Medicine underpinned Glivec (imatinib)[*] as a durable and well...
- Glivec sets new treatment standard in chronic myeloid leukemia with high...
- News wire article from: Europe Intelligence Wire June 3, 2006 700+ words
...mortality due to CML * Response rate to Glivec increases substantially over five...continues to drop the longer patients take Glivec, falling to 0.6% in fifth year Basel, June 3, 2006 - Response rates to Glivec (imatinib) continue to increase...
- Glivec[R] approved in Japan for treatment of life-threatening gastrointestinal...
- News wire article from: Europe Intelligence Wire July 17, 2003 700+ words
...health authorities in Japan have approved Glivec[R] (imatinib)* for the treatment...after Novartis filed for the indication. Glivec was originally granted Orphan Drug status...European Union and the United States, where Glivec is already approved for this indication...
Source: HighBeam Research, New Drug Continues to Show Promise in Early Testing.
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA
The AccessMyLibrary advertising network includes:
